We assessed the respective anti-tumor activity of the following PI3K/AKT/mTOR pathway inhibitors: BEZ235 (dual inhibitor of PI3K, mTORC1 and mTORC2), BKM120 (PI3K inhibitor) and everolimus (mTORC1 inhibitor). This evidence concerns the gene MTOR and neoplasm.